Paragon Bioservices, Inc. (Paragon), the leading private equity-backed biologics contract development and manufacturing organization (CDMO) with proven expertise in gene therapy and next-generation vaccines, today announced it was named to Deloitte’s Technology Fast 500™ for 2018, a ranking of the 500 fastest growing technology, media, telecommunications, life sciences and energy tech companies in North America. Additionally, Paragon was named #8 to the Baltimore Business Journal’s Fast 50 for the second year in a row.
{iframe}https://www.prnewswire.com/news-releases/paragon-bioservices-named-to-deloittes-technology-fast-500-300752813.html{/iframe}